Skip to results
Modify your search
NARROW
1-20 of 65
Authors: Michael D. Prados
Journal Article
IMG-04. RESPONSE ASSESSMENT IN PEDIATRIC HIGH-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY WORKING GROUP Open Access
Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii355, https://doi.org/10.1093/neuonc/noaa222.340
Published: 04 December 2020
Journal Article
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma Free
Neuro-Oncology, Volume 20, Issue 10, October 2018, Pages 1411–1418, https://doi.org/10.1093/neuonc/noy054
Published: 05 April 2018
Journal Article
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy Open Access
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 259–267, https://doi.org/10.1093/neuonc/nox151
Published: 03 October 2017
Journal Article
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy Open Access
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 249–258, https://doi.org/10.1093/neuonc/nox154
Published: 14 August 2017
Journal Article
DIPG-29. GENOMIC LANDSCAPE OF DIFFUSE INTRINSIC PONTINE GLIOMA: AN ANALYSIS OF THE DIPG-BATS COHORT Free
Neuro-Oncology, Volume 19, Issue suppl_4, June 2017, Page iv11, https://doi.org/10.1093/neuonc/nox083.044
Published: 31 May 2017
Journal Article
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee Free
Neuro-Oncology, Volume 20, Issue 1, January 2018, Pages 13–23, https://doi.org/10.1093/neuonc/nox087
Published: 25 April 2017
Journal Article
Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth Free
Neuro-Oncology, Volume 18, Issue 11, November 2016, Pages 1519–1528, https://doi.org/10.1093/neuonc/now106
Published: 01 July 2016
Journal Article
EDITOR'S CHOICE
Toward precision medicine in glioblastoma: the promise and the challenges Get access
Neuro-Oncology, Volume 17, Issue 8, August 2015, Pages 1051–1063, https://doi.org/10.1093/neuonc/nov031
Published: 01 May 2015
Journal Article
HG-13SOX9 AS A DOWN-STREAM TARGET IN RAS/MEK-DRIVEN PEDIATRIC GLIOMA Get access
Neuro-Oncology, Volume 17, Issue suppl_3, June 2015, Page iii13, https://doi.org/10.1093/neuonc/nov061.50
Published: 21 April 2015
Journal Article
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD) Get access
Neuro-Oncology, Volume 16, Issue suppl_7, October 2014, Pages vii36–vii47, https://doi.org/10.1093/neuonc/nou226
Published: 01 October 2014
Journal Article
Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group Get access
Neuro-Oncology, Volume 17, Issue 2, February 2015, Pages 180–188, https://doi.org/10.1093/neuonc/nou154
Published: 26 August 2014
Journal Article
SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) ASSOCIATED WITH GLIOMA SURVIVAL Get access
Neuro-Oncology, Volume 16, Issue suppl_3, July 2014, Page iii2, https://doi.org/10.1093/neuonc/nou206.7
Published: 01 July 2014
Journal Article
RB1 SUPPRESSION IS RESPONSIBLE FOR ACQUIRED CDK4/6 INHIBITOR RESISTANCE IN GLIOBLASTOMA Get access
Neuro-Oncology, Volume 16, Issue suppl_3, July 2014, Pages iii33–iii34, https://doi.org/10.1093/neuonc/nou208.41
Published: 01 July 2014
Journal Article
PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA CONDUCTED BY THE IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM Get access
Neuro-Oncology, Volume 16, Issue suppl_3, July 2014, Page iii47, https://doi.org/10.1093/neuonc/nou209.20
Published: 01 July 2014
Journal Article
TELOMERE LENGTH VARIANTS ARE ASSOCIATED WITH HIGH-GRADE GLIOMA RISK: IDENTIFICATION OF A NOVEL GLIOMA RISK LOCUS BY GENOME-WIDE ASSOCIATION STUDY Get access
Neuro-Oncology, Volume 16, Issue suppl_3, July 2014, Page iii2, https://doi.org/10.1093/neuonc/nou206.4
Published: 01 July 2014
Journal Article
Plexiform neurofibromas, trial design, and the definitions of “progression” and “treatment failure” Get access
Neuro-Oncology, Volume 16, Issue 5, May 2014, Pages 617–618, https://doi.org/10.1093/neuonc/nou050
Published: 01 May 2014
Journal Article
“We will know it when we see it;” bevacizumab and glioblastoma Get access
Neuro-Oncology, Volume 16, Issue 4, April 2014, Pages 469–470, https://doi.org/10.1093/neuonc/nou036
Published: 01 April 2014
Journal Article
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma Get access
Neuro-Oncology, Volume 16, Issue 9, September 2014, Pages 1255–1262, https://doi.org/10.1093/neuonc/nou044
Published: 26 March 2014
Journal Article
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma Get access
Neuro-Oncology, Volume 16, Issue 7, July 2014, Pages 984–990, https://doi.org/10.1093/neuonc/nou029
Published: 16 March 2014
Journal Article
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 Get access
Neuro-Oncology, Volume 16, Issue 4, April 2014, Pages 567–578, https://doi.org/10.1093/neuonc/not247
Published: 26 January 2014
